FY2025 · ended Dec 31, 2025 · Revenue $590,084, -65.5% YoY · Filed Mar 30, 2026
Pmgc Holdings Inc. (ELAB) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $590,084 and a net loss of $7.7 million. Free cash flow was -$6.4 million. As of Jun 30, 2026 it held $18.8 million in cash and investments and $5.2 million in total debt.
Revenue
$590,084
-65.5% vs prior year
Net income (TTM)
$-13.49M
-140.5% vs year-ago TTM
Operating cash flow (TTM)
$-8.21M
-61.7% vs year-ago TTM
Free cash flow (TTM)
$-8.98M
EPS
$-0.40
Dividend per share
None
Shares outstanding
1.16M
+63.9% vs prior year
Net cash
$13.63M
as of Jun 30, 2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ELAB (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Newport Beach, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1840563
- Former names
- Elevai Labs Inc. (until Nov 27, 2024); Reactive Medical Labs Inc. (until Oct 14, 2021)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
|---|---|---|---|
| Revenue | $590,084 | — | $1.7M |
| Net income | -$7.7M | -$6.2M | -$4.3M |
| Diluted EPS | — | — | -$0.40 |
| Operating cash flow | -$5.9M | -$5.5M | -$4.6M |
| Free cash flow | -$6.4M | -$5.5M | — |
| Total assets | $12.9M | $9.0M | $5.2M |
| Total liabilities | $5.0M | $2.3M | $1.4M |
| Stockholders' equity | $7.8M | $6.7M | $3.8M |
| Cash and investments | $6.0M | $139,084 | $3.3M |
| Total debt | $1.2M | — | $210,489 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement
|
Nov 2, 2026 | Oct 30, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Oct 28, 2026 | Oct 28, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 18, 2026 | Sep 18, 2026 |
| 8-K |
Current report
Material agreement, Change to shareholder rights, Bylaw or fiscal year change, Regulation FD disclosure
|
Sep 2, 2026 | Aug 27, 2026 |
| 8-K |
Current report
Material agreement, Change to shareholder rights, Bylaw or fiscal year change, Regulation FD disclosure, Other events
|
Aug 27, 2026 | Aug 21, 2026 |
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
All 273 Pmgc Holdings Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.